Whitehawk Therapeutics (WHWK) Price & Analysis

Compare

497 Followers

WHWK Stock Chart & Stats

$2.59

Market closed

$2.59

Day’s Range― - ―

52-Week Range$1.39 - $3.81

Previous CloseN/A

VolumeN/A

Average Volume (3M)3.35M

Market Cap

$106.51M

Enterprise Value-$48.01M

Total Cash (Recent Filing)$177.20M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.52

Next Earnings

Mar 12, 2026

EPS Estimate

-0.69

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding47,128,360

10 Day Avg. Volume9,835,549

30 Day Avg. Volume3,352,856

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.63

Price to Sales (P/S)3.29

P/FCF Ratio-1.40

Enterprise Value/Market Cap-0.45

Enterprise Value/Revenue-2.22

Enterprise Value/Gross Profit9.41

Enterprise Value/Ebitda0.50

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial StabilityWhitehawk ended 2Q25 with $162.6M in cash, cash equivalents, and marketable securities, which should provide an operational runway into 2028.

Product DevelopmentManagement is confident that HWK-007 is poised to overcome toxicity challenges and could improve upon ORRs by 20% or more to the 40-50% range in all comers.

Regulatory MilestonesWhitehawk remains on track for INDs for all 3 next-gen ADCs in the next ~9 months.

Bears Say

Financial PerformanceWhitehawk recorded a net loss of $0.26 per share vs. our previously estimated net loss of $0.22 per share.

Market RisksRisks originally included, but were not limited to: disappointing market uptake of FYARRO in the PEComa indication and inability to develop FYARRO in other cancers.

Operational CostsR&D and SG&A expenses were $14.3M and $5.2M, respectively, vs. our estimates of $11.0M and $6.1M.

Whitehawk Therapeutics News

Whitehawk Therapeutics appoints Dugan as Chief Medical Officer

Whitehawk Therapeutics (WHWK) announced the appointment of Margaret Dugan, MD, as Chief Medical Officer, CMO. Dr. Dugan brings...

10d ago

WHWK

Whitehawk Therapeutics Reports Q3 2025 Financial Results

Aadi Bioscience, Inc. ( ($WHWK) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

WHWK

Cautious Optimism for Whitehawk Therapeutics: Balancing Innovation with Risk in Next-Gen ADCs

TD Cowen analyst Tara Bancroft has maintained their neutral stance on WHWK stock, giving a Hold rating today....

1M ago

WHWK

Cautious Outlook on Whitehawk Therapeutics Amid Financial Challenges and Clinical Uncertainties

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on WHWK stock, giving a Hold rating on...

1M ago

WHWK

Whitehawk Therapeutics reports Q3 EPS (26c) vs. (46c) last year

Reports Q3 revenue $0, consensus $33.33M. Cash, cash equivalents and short-term investments as of September 30, 2025, were...

1M ago

WHWK

Tempus AI enters pact with Whitehawk Therapeutics to advance oncology research

Tempus AI (TEM) announced a multi-year collaboration with Whitehawk Therapeutics (WHWK). The collaboration aims to leverage Tempus’ proprietary...

2M ago

TEM

WHWK

Whitehawk Therapeutics Advances ADC Portfolio Amid Financial Growth

Aadi Bioscience, Inc. ( ($WHWK) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

WHWK

Cautious Optimism for Whitehawk Therapeutics Amid Strategic ADC Advancements

TD Cowen analyst Tara Bancroft has maintained their neutral stance on WHWK stock, giving a Hold rating on...

4M ago

WHWK

Whitehawk Therapeutics Elects Directors at Annual Meeting

Whitehawk Therapeutics ( ($WHWK) ) just unveiled an update. Whitehawk Therapeutics, Inc. held its annual meeting of stockholders...

6M ago

WHWK

Whitehawk Therapeutics Reports Strong Q1 2025 Results

Aadi Bioscience, Inc. ( ($WHWK) ) has released its Q1 earnings. Here is a breakdown of the information...

7M ago

WHWK

Whitehawk Therapeutics files to sell 41.67M shares of common stock for holders

The company will not receive any proceeds from the sale of the shares offered by this prospectus. Published...

8M ago

WHWK

Aadi Bioscience’s Earnings Call: Strategic Shifts and Promising Pipeline

Aadi Bioscience, Inc. (($WHWK)) has held its Q4 earnings call. Read on for the main highlights of the...

9M ago

WHWK

WHWK FAQ

What was Whitehawk Therapeutics’s price range in the past 12 months?

Whitehawk Therapeutics lowest stock price was $1.39 and its highest was $3.81 in the past 12 months.

What is Whitehawk Therapeutics’s market cap?

Whitehawk Therapeutics’s market cap is $106.51M.

When is Whitehawk Therapeutics’s upcoming earnings report date?

Whitehawk Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 91 days.

How were Whitehawk Therapeutics’s earnings last quarter?

Whitehawk Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of $0.067 by -$0.327.

Is Whitehawk Therapeutics overvalued?

According to Wall Street analysts Whitehawk Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Whitehawk Therapeutics pay dividends?

Whitehawk Therapeutics does not currently pay dividends.

What is Whitehawk Therapeutics’s EPS estimate?

Whitehawk Therapeutics’s EPS estimate is -0.69.

How many shares outstanding does Whitehawk Therapeutics have?

Whitehawk Therapeutics has 47,128,360 shares outstanding.

What happened to Whitehawk Therapeutics’s price movement after its last earnings report?

Whitehawk Therapeutics reported an EPS of -$0.26 in its last earnings report, missing expectations of $0.067. Following the earnings report the stock price went down -6.667%.

Which hedge fund is a major shareholder of Whitehawk Therapeutics?

Currently, no hedge funds are holding shares in WHWK

Whitehawk Therapeutics Stock Smart Score

Underperform

Analyst Consensus

Hold

Average Price Target:
― (―)

Technicals

Fundamentals

Return on Equity

-13.82%

Trailing 12-Months

Asset Growth

77.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Whitehawk Therapeutics

Whitehawk Therapeutics (WHWK) is a biopharmaceutical company focused on developing innovative therapeutics that target immune-mediated diseases. The company operates primarily in the biotechnology sector, specializing in the discovery and development of novel treatments that leverage the immune system to combat various conditions. Whitehawk Therapeutics aims to provide transformative therapies that improve patient outcomes in areas with significant unmet medical needs.

Whitehawk Therapeutics (WHWK) Earnings & Revenues

Historic Earnings Reports

WHWK Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.4,2.2153846153846155,2.0307692307692307,1.8461538461538463,1.6615384615384614,1.476923076923077,1.2923076923076924,1.1076923076923078,0.9230769230769231,0.7384615384615385,0.5538461538461539,0.36923076923076925,0.18461538461538485,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.4,2.2153846153846155,2.0307692307692307,1.8461538461538463,1.6615384615384614,1.476923076923077,1.2923076923076924,1.1076923076923078,0.9230769230769231,0.7384615384615385,0.5538461538461539,0.36923076923076925,0.18461538461538485,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.4,2.2153846153846155,2.0307692307692307,1.8461538461538463,1.6615384615384614,1.476923076923077,1.2923076923076924,1.1076923076923078,0.9230769230769231,0.7384615384615385,0.5538461538461539,0.36923076923076925,0.18461538461538485,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.52,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >